| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
The primary targets of 2,4-Dihydroxybenzaldehyde include iNOS and COX-2, whose expression it inhibits to reduce NO and ROS production. It also targets phenoloxidase, with IC50 values of 4.88 µM and 204.17 µM. The compound exhibits anti-angiogenic, anti-inflammatory, and analgesic activities. As a resorcinol derivative, it has potent antioxidant and antibacterial activities. These targets make it relevant for inflammation, pain, and infectious disease research.
|
|---|---|
| ln Vitro |
In vitro, 2,4-Dihydroxybenzaldehyde reduces NO and ROS production by inhibiting iNOS and COX-2 expression. It exhibits significant anti-angiogenic, anti-inflammatory, and analgesic activities. The compound acts as an inhibitor of Pieris rapae phenoloxidase with IC50 values of 4.88 µM and 204.17 µM. It demonstrates potent antioxidant and antibacterial activity. These in vitro activities support its use in inflammation, pain, angiogenesis, and infectious disease research.
|
| ln Vivo |
In vivo, 2,4-Dihydroxybenzaldehyde has demonstrated anti-inflammatory, anti-angiogenic, and anti-nociceptive activities. Its anti-inflammatory and anti-nociceptive properties suggest potential as a therapeutic agent for inflammatory diseases and pain management. However, detailed in vivo efficacy data are limited. As an endogenous metabolite, it is naturally present in biological systems. Further studies are needed to evaluate its therapeutic potential in animal models of inflammation and pain.
|
| Enzyme Assay |
In vitro enzyme assays for 2,4-Dihydroxybenzaldehyde involve measuring iNOS and COX-2 inhibition. Cells or enzyme preparations are incubated with compound concentrations ranging from 0.1-1000 μM. iNOS and COX-2 expression is measured by Western blot or ELISA. NO production is measured using Griess reagent. ROS production is measured using fluorescent probes. Phenoloxidase inhibition is assessed using enzyme activity assays with appropriate substrates. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for 2,4-Dihydroxybenzaldehyde are conducted using macrophages, endothelial cells, or other relevant cell lines. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. NO and ROS levels are measured. Inflammatory cytokine production is assessed by ELISA. Angiogenesis is evaluated using endothelial tube formation assays. Antibacterial activity is assessed using bacterial cultures. Cell viability is assessed using MTT assays. Experiments include vehicle controls and positive controls.
|
| Animal Protocol |
In vivo animal studies with 2,4-Dihydroxybenzaldehyde are limited, as the compound is primarily used as a research tool. Anti-inflammatory studies may be conducted in rodent models of acute inflammation (e.g., carrageenan-induced paw edema). Analgesic activity is assessed in pain models. Anti-angiogenic activity is evaluated in angiogenesis models. The compound is administered via intraperitoneal or oral routes at doses ranging from 1-50 mg/kg. Each group consists of 6-10 animals with vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,4-Dihydroxybenzaldehyde have not been extensively characterized. As a small, polar molecule (MW 138.12, C7H6O3), it is expected to have moderate oral bioavailability and reasonable tissue distribution. The compound is an endogenous metabolite and likely undergoes hepatic metabolism through conjugation (glucuronidation and sulfation), with elimination via renal excretion. Detailed PK parameters require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,4-Dihydroxybenzaldehyde indicate that it is generally well-tolerated at concentrations used for research. As an endogenous metabolite, it is expected to have a favorable safety profile. No significant toxicity has been reported. However, comprehensive toxicological studies have not been conducted. As with all research chemicals, appropriate safety precautions should be taken during handling, and the compound should be used only for research purposes.
|
| Additional Infomation |
2,4-Dihydroxybenzaldehyde is a dihydroxybenzaldehyde, a compound in which one of the hydroxyl groups of resorcinol is replaced at the para-position by a formyl group. It has been reported to exist in mulberry trees (Morus macroura), white-flowered Bonninghausenia albiflora, and other organisms with relevant data.
2,4-Dihydroxybenzaldehyde is an endogenous metabolite and resorcinol derivative with potent antioxidant and antibacterial activity. It exhibits significant anti-angiogenic, anti-inflammatory, and analgesic activities by reducing NO and ROS production through iNOS and COX-2 inhibition. It inhibits Pieris rapae phenoloxidase. The compound is a pharmaceutical intermediate for synthesizing Schiff base compounds. Not approved for clinical therapeutic use; intended for research purposes. |
| Molecular Formula |
C₇H₆O₃
|
|---|---|
| Molecular Weight |
138.12
|
| Exact Mass |
138.031
|
| CAS # |
95-01-2
|
| PubChem CID |
7213
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
350.7±0.0 °C at 760 mmHg
|
| Melting Point |
135-137 °C(lit.)
|
| Flash Point |
165.9±16.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.674
|
| LogP |
1.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
124
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IUNJCFABHJZSKB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6O3/c8-4-5-1-2-6(9)3-7(5)10/h1-4,9-10H
|
| Chemical Name |
2,4-dihydroxybenzaldehyde
|
| Synonyms |
2,4Dihydroxybenzaldehyde; 2,4 Dihydroxybenzaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~724.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2401 mL | 36.2004 mL | 72.4008 mL | |
| 5 mM | 1.4480 mL | 7.2401 mL | 14.4802 mL | |
| 10 mM | 0.7240 mL | 3.6200 mL | 7.2401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
